Fujian University of Traditional Chinese Medicine, Fujian, China.
Cancer Epidemiol. 2012 Feb;36(1):94-8. doi: 10.1016/j.canep.2011.02.001. Epub 2011 Apr 6.
The preferential metastasis of cancer cells to skeleton not only disrupts the process of bone remodeling and influences the therapeutic decision, but also results in severe complications. Although the current diagnosis of bone metastases (BM) relies on bone imaging techniques, they are not sensitive enough for early detection as well as they are invasive and expensive to use. Since factors derived from bone metabolism are potentially useful to diagnose metastatic bone disease in cancer patients, a number of clinical trials have been carried out on this area. Results suggest that higher levels of bone biomarkers are associated with an increased risk of BM. As a result, biochemical-markers are showing prospects in early diagnosis of BM. This review summarizes the available evidence on the clinical use of biochemical-markers in the diagnosis of various cancers with high incidence of BM including breast, prostate and lung.
癌细胞向骨骼的优先转移不仅破坏了骨重塑的过程并影响了治疗决策，而且还导致严重的并发症。尽管目前骨转移（BM）的诊断依赖于骨成像技术，但它们对于早期检测的敏感性不够，并且使用起来具有侵入性和昂贵。由于源自骨代谢的因素对于诊断癌症患者的转移性骨疾病可能是有用的，因此已经在该领域进行了许多临床试验。结果表明，较高水平的骨生物标志物与 BM 的风险增加相关。因此，生化标志物在 BM 的早期诊断中显示出了前景。这篇综述总结了关于在包括乳腺癌、前列腺癌和肺癌在内的 BM 发生率较高的各种癌症的诊断中使用生化标志物的临床应用的现有证据。
